Virtus Health is a purpose-driven organisation, working to continuously improve patient care. Virtus Health is working towards a future where everyone in the community has the opportunity to create a family. Virtus is one of the top five providers of assisted reproductive services in the world with a presence in Australia, Singapore, Ireland, the UK and Denmark.

Virtus Health is backing 23Strands. The collaboration combines the leading developments in 21st-century medicine – genetics, artificial intelligence, and the power of data analytics.

The Australian Genome Research Facility (AGRF) is Australia’s largest provider of genomics services. It provides genotyping, next-generation sequencing, microarray, DNA sequencing and bioinformatics services. AGRF has signed a Heads of Agreement (HoA) with 23Strands to be their partner in developing Whole Genome Sequencing for clinical use.

Datar Cancer genetics is a world-leading molecular oncology facility with a fully equipped laboratory, integrated process platforms, in-house bioinformatics team, and a huge genetic database for precise and updated reporting. The company offer highly effective treatment solutions to cancer patients for whom, multiple lines of treatment have failed.

Datar Cancer Genetics is a key clinical partner, 23Strands has signed an agreement with Datar Cancer Genetics to sell Datar's proven protocol for deep genomics driven cancer therapy optimisation.

Oracle's mission is to help people see data in new ways, discover insights and unlock endless possibilities. We have partnered with Oracle and are receiving support from its Global Health team.

As Australia's most comprehensive university entrepreneurship program, UNSW Founders comprises multiple programs and services that can foster ideas from its earliest stage right through to a startup that's ready to go global.

23 Strands participated in Health 10x 2020 program, Cohort #2, and we were chosen for our potential to improve healthcare in emerging markets.

At the core of the Australian company, Haventec is a bold idea aiming to protect digital identities from harm, a crucial pillar of digital trust. The company has developed award-winning decentralised platforms that eliminate the need to store digital identities, credentials, and data centrally.

As a critical commercial partner, Haventec has collaborated with 23Strands to deliver a new and innovative digital health consent solution – eConsent for Genomics.

The Australian Cardiovascular Alliance (ACvA) is the peak leadership body in the country for the advancement of heart disease research. It is a comprehensive collaboration of the highest quality cardiovascular research bodies and scientific societies, individual researchers, industry and non-government organisations in Australia.

The Australian Cardiovascular Alliance, headed by Gemma Figtree, received a grant in early 2021 to implement polygenic risk scores to manage the risks of coronary artery disease more effectively. 23Strands is an essential industry partner in this study and are responsible for the in-depth analysis of genomic information from recruited patients, utilising machine learning techniques.

The Australian Artificial Intelligence Institute (AAII) at UTS is a world-leading research institute in artificial intelligence (AI), with a vision to develop theoretical foundations and advanced algorithms for AI and to drive significant progress in related areas like computational intelligence, data science, machine learning, bioinspired neural networks and information systems.

UTS and the Australian Artificial Intelligence Institute (AAII) has signed a Master Collaboration Agreement with 23Strands to bring next-generation techniques in Natural Language Processing (NLP), AI and ML empowered risk scoring and recommendation engine development to genomics for clinical use.

The Baker Heart and Diabetes Institute is an independent, internationally renowned medical research facility. The Institute's work extends from the laboratory to wide-scale community studies with a focus on diagnosis, prevention and treatment of diabetes, cardiovascular disease and associated metabolic diseases.

Recently the Baker Heart and Diabetes Institute have received a grant for the “early identification and treatment of heart disease to prevent heart attacks” in partnership with 23strands. Together we are striving to create models and tools to assess risk and identify personalised prevention methods to counteract cardiovascular disease.

InGeNA is an alliance between a broad group of industry organisations formed to bring a shared perspective on critically important areas underpinning the future of genomics. InGeNA is a single voice for Australian industry partners contributing to the rapidly developing field of genomics.

23Strands is proud to announce that it is part of the 13 founding members that have joined InGeNA as a peak industry genomics body.

The Ingham Institute for Applied Medical Research signs a Master Collaborative Research Agreement with 23Strands. This agreement solidifies relationship with the Sydney South West region, in particular Liverpool hospital and will be the basis for mutually beneficial programs, projects and activities including collaborative research on the clinical utility of genomics in clinical practice.

The university became the first in the world to be successful in human IVF pregnancy in 1973 which was a product of the Monash In Vitro Fertilisation research program, started as a combined project between Monash University and the University of Melbourne.

Monash University has signed a Master Research Agreement with 23Strands for the development of Whole Human Genome Sequencing based translational research into clinical use.